Searched for
SEMAGLUTIDE SYRINGES
Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block dealShares of Alkem Laboratories will be in focus after block deals worth around Rs 930 crore saw 17.88 lakh shares traded at Rs 5,200 apiece o...- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...
- Biocon rolls out two biosimilars in US marketBiocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They...
- Natco beats rivals with Rs 1,290 semaglutide launch as Novo Nordisk patent expiresNatco Pharma introduces a new, affordable semaglutide injection in multidose vials. This launch coincides with the patent expiry of the inn...
- Weight is over! Pharma stocks jump up to 4% as patent for Ozempic's key ingredient expires; what lies ahead?Pharma stocks rose up to 4% as Novo Nordisk’s semaglutide patent nears expiry, raising expectations of cheaper generics in India. Strong gr...
- Natco launches Rs 1,290 semaglutide in India, undercuts diabetes drug pricesNatco Pharma has launched a new generic semaglutide injection in India. This marks a significant step in making advanced diabetes treatment...
- 'Chinese peptides' are the latest biohacking trend in the tech worldTech professionals are embracing unapproved Chinese peptides for weight loss, fitness, and productivity. These substances, often sourced di...
- Pharma stocks: Time to change the prescription? 13 pharma stocks with an upside potential of up to 39%Close to three decades back, when Indian pharma firms began to move into the US market, they faced many challenges. And the fact is that th...
- Novo Nordisk bets on cheaper Ozempic to dominate India’s booming weight-loss marketNovo Nordisk has launched Ozempic in India at a competitive price, aiming to capture a significant share of the growing weight-loss market....
- Natco Pharma sues Novo Nordisk in generic drug pushThe lawyers representing Natco Pharma informed the court that over the past few months it had approached Novo Nordisk to communicate on its...
- Weight-loss drug boom likely to fuel an injector pen makerAs weight-loss drug sales surge with semaglutide's patent expiration, Gujarat's Shaily Engineering Plastics, an injector pen manufacturer, ...
- Novo Nordisk’s Wegovy enters India: Can this weight loss jab beat Mounjaro? Price, who can use it & how it worksNovo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy conta...
- Novo Nordisk aims for heavy sales in India with WegovyThe achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record for prescriptio...
Load More
